Literature DB >> 25997128

Science to Practice: Monitoring Oncolytic Virus Therapy with Chemical Exchange Saturation Transfer MR Imaging--Wishful Thinking?

Peter L Choyke1.   

Abstract

Farrar et al demonstrate that modifying an oncolytic virus (OV) so that it produces excess protein when it infects a cancer cell is a process that can be detected both in vitro and in vivo in infected cancer cells by using chemical exchange saturation transfer (CEST) magnetic resonance (MR) imaging. The effect is at the limits of MR imaging detection (approximately 1%), but experience with functional MR imaging of the brain, with comparably small effects, should give pause to anyone who immediately writes this observation off as an exercise in wishful thinking. OVs are improving in their specificity, virulence, and ability to induce immune responses. Now, they have been modified to express proteins that are detectable with CEST MR imaging early after delivery into a tumor. This is clearly a surprising and hopeful development in the long road of OVs from the laboratory to the clinic.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25997128      PMCID: PMC4450909          DOI: 10.1148/radiol.2015150537

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  5 in total

Review 1.  Tracking immune cells in vivo using magnetic resonance imaging.

Authors:  Eric T Ahrens; Jeff W M Bulte
Journal:  Nat Rev Immunol       Date:  2013-09-10       Impact factor: 53.106

2.  Establishing the Lysine-rich Protein CEST Reporter Gene as a CEST MR Imaging Detector for Oncolytic Virotherapy.

Authors:  Christian T Farrar; Jason S Buhrman; Guanshu Liu; Anne Kleijn; Martine L M Lamfers; Michael T McMahon; Assaf A Gilad; Giulia Fulci
Journal:  Radiology       Date:  2015-02-13       Impact factor: 11.105

Review 3.  A review of responsive MRI contrast agents: 2005-2014.

Authors:  Dina V Hingorani; Adam S Bernstein; Mark D Pagel
Journal:  Contrast Media Mol Imaging       Date:  2014-10-29       Impact factor: 3.161

Review 4.  Going viral with cancer immunotherapy.

Authors:  Brian D Lichty; Caroline J Breitbach; David F Stojdl; John C Bell
Journal:  Nat Rev Cancer       Date:  2014-07-03       Impact factor: 60.716

Review 5.  Oncolytic virotherapy.

Authors:  Stephen J Russell; Kah-Whye Peng; John C Bell
Journal:  Nat Biotechnol       Date:  2012-07-10       Impact factor: 54.908

  5 in total
  1 in total

1.  Contradiction between amide-CEST signal and pH in breast cancer explained with metabolic MRI.

Authors:  Erwin Krikken; Wybe J M van der Kemp; Vitaliy Khlebnikov; Thijs van Dalen; Maartje Los; Hanneke W M van Laarhoven; Peter R Luijten; Maurice A A J van den Bosch; Dennis W J Klomp; Jannie P Wijnen
Journal:  NMR Biomed       Date:  2019-05-28       Impact factor: 4.044

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.